Back to News
Market Impact: 0.15
SeaStar Medical Congratulates H. David Humes, M.D., on Receiving the University of Michigan 2026 Distinguished University Innovator of the Year for Development of the SCD Therapy
Source: GlobeNewswire
Healthcare & BiotechProduct LaunchesTechnology & Innovation
Dr. Humes received a prestigious honor for pioneering the Selective Cytopheretic Device (SCD) therapy. SeaStar Medical has commercialized the therapy as QUELIMMUNE for critically ill pediatric patients with acute kidney injury, highlighting external recognition of its medical-device innovation.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
ICU0.75
More News
- Trump Versus Xi: How Their High-Stakes Summits Compare
- Trump, Xi Address AI, Taiwan During State Visit
- Oracle Japan shares surge 7% after record fiscal first quarter, bucking selloff of U.S. parent
- China's Xi urges U.S. to cooperate on AI
- Akamai secures $11.6B cloud deal with Anthropic for AI workloads
- U.S. government seeks to join Elon Musk in challenge against EU's fine on X